8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 6, 2026·SEC
Repligen Corporation(RGEN)Earnings, Financials & Key Ratios
RGEN•NASDAQ
153.5× P/E·Price updated Jun 19, 2026
AboutRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$738M+16.4%
- EBITDA$138M+168.9%
- Net Income$49M+291.6%
- EPS (Diluted)0.86+287.0%
- Gross Margin47.09%+8.8%
- EBITDA Margin18.74%+131.1%
- Operating Margin8.07%+245.8%
- Net Margin6.62%+264.7%
- ROE2.4%+285.0%
RGEN Key Insights
Repligen Corporation (RGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 15.0%
- ✓Healthy 5Y average net margin of 10.1%
✗Weaknesses
- ✗Weak 3Y average ROE of 1.0%
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RGEN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RGEN Price & Volume
Repligen Corporation (RGEN) stock price & volume — 10-year historical chart
Loading chart...
RGEN Growth Metrics
Repligen Corporation (RGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years24.35%
5 Years15.05%
3 Years-2.7%
TTM17.36%
Profit CAGR
10 Years18%
5 Years-3.99%
3 Years-35.94%
TTM323.66%
EPS CAGR
10 Years11.88%
5 Years-4.98%
3 Years-35.73%
TTM842.57%
Return on Capital
10 Years10%
5 Years4.63%
3 Years0.95%
Last Year2.16%
RGEN Recent Earnings
Repligen Corporation (RGEN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.48+26.3%
$0.38
Rev
$194M+1.1%
$192M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.49+11.4%
$0.44
Rev
$198M+2.6%
$193M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$0.46+9.5%
$0.42
Rev
$189M-1.8%
$192M
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.37-7.5%
$0.40
Rev
$182M+0.3%
$182M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.48vs $0.38+26.3% | $194Mvs $192M+1.1% |
| Q1 2026 | Feb 24, 2026 | $0.49vs $0.44+11.4% | $198Mvs $193M+2.6% |
| Q4 2025 | Oct 28, 2025 | $0.46vs $0.42+9.5% | $189Mvs $192M-1.8% |
| Q3 2025 | Jul 29, 2025 | $0.37vs $0.40-7.5% | $182Mvs $182M+0.3% |
Based on last 12 quarters of dataView full earnings history →
RGEN Peer Comparison
Repligen Corporation (RGEN) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FTRE | 1.45B | 15.31 | -1.42 | 1% | -16.5% | -79.12% | 0.12 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 AZTA | 1.07B | 23.31 | -19.11 | 3.55% | -29.86% | -10.69% | 0.06 | |
 BRKR | 8.71B | 57.23 | -381.53 | 2.08% | -0.34% | -0.5% | 0.81 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 | |
 ICLR | 11.18B | 146.00 | 50.34 | -0.37% | 5.98% | 5.2% | 0.39 |
Compare RGEN vs Peers
Repligen Corporation (RGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RGEN Income Statement
Repligen Corporation (RGEN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 141.24M | 194.03M | 270.25M | 366.26M | 670.53M | 801.54M | 632.36M | 634.44M | 738.26M | 763.34M |
Revenue Growth % | 35.1% | 37.38% | 39.28% | 35.53% | 83.08% | 19.54% | -21.11% | 0.33% | 16.36% | 17.36% |
Cost of Goods Sold | 67.05M | 85.95M | 132.02M | 171.91M | 279.28M | 345.83M | 353.92M | 359.79M | 390.63M | 283.98M |
COGS % of Revenue | 47.47% | 44.3% | 48.85% | 46.94% | 41.65% | 43.15% | 55.97% | 56.71% | 52.91% | - |
Gross Profit | 74.19M▲ 0% | 108.08M▲ 45.7% | 138.22M▲ 27.9% | 194.35M▲ 40.6% | 391.25M▲ 101.3% | 455.71M▲ 16.5% | 278.44M▼ 38.9% | 274.64M▼ 1.4% | 347.62M▲ 26.6% | 393.38M▲ 0% |
Gross Margin % | 52.53% | 55.7% | 51.15% | 53.06% | 58.35% | 56.85% | 44.03% | 43.29% | 47.09% | 51.53% |
Gross Profit Growth % | 29.19% | 45.69% | 27.89% | 40.61% | 101.31% | 16.47% | -38.9% | -1.36% | 26.57% | - |
Operating Expenses | 60.18M | 82.09M | 98.14M | 113.07M | 224M | 231.04M | 230.74M | 309.76M | 288.05M | 326.82M |
OpEx % of Revenue | 42.61% | 42.31% | 36.32% | 30.87% | 33.41% | 28.82% | 36.49% | 48.82% | 39.02% | - |
Selling, General & Admin | 51.51M | 66.32M | 78.69M | 93.41M | 183.87M | 215.83M | 218.58M | 263.37M | 290.51M | 284.13M |
SG&A % of Revenue | 36.47% | 34.18% | 29.12% | 25.5% | 27.42% | 26.93% | 34.57% | 41.51% | 39.35% | - |
Research & Development | 8.67M | 15.77M | 19.45M | 19.66M | 34.27M | 43.94M | 42.72M | 43.2M | 54.18M | 54.77M |
R&D % of Revenue | 6.14% | 8.13% | 7.2% | 5.37% | 5.11% | 5.48% | 6.76% | 6.81% | 7.34% | - |
Other Operating Expenses | 0 | 262K | 0 | 0 | 5.87M | -28.73M | -30.57M | 3.19M | -56.64M | -2M |
Operating Income | 14.01M▲ 0% | 25.99M▲ 85.6% | 40.08M▲ 54.2% | 81.29M▲ 102.8% | 167.25M▲ 105.7% | 224.67M▲ 34.3% | 47.7M▼ 78.8% | -35.11M▼ 173.6% | 59.58M▲ 269.7% | 66.57M▲ 0% |
Operating Margin % | 9.92% | 13.39% | 14.83% | 22.19% | 24.94% | 28.03% | 7.54% | -5.53% | 8.07% | 8.72% |
Operating Income Growth % | -12.33% | 85.56% | 54.24% | 102.8% | 105.75% | 34.33% | -78.77% | -173.61% | 269.67% | - |
EBITDA | 24.46M | 41.77M | 60.95M | 108.36M | 205.7M | 281.68M | 133.82M | 51.45M | 138.32M | 155.46M |
EBITDA Margin % | 17.32% | 21.53% | 22.55% | 29.58% | 30.68% | 35.14% | 21.16% | 8.11% | 18.74% | 20.37% |
EBITDA Growth % | 14.78% | 70.77% | 45.93% | 77.77% | 89.84% | 36.94% | -52.49% | -61.55% | 168.86% | 132.55% |
D&A (Non-Cash Add-back) | 10.45M | 15.78M | 20.87M | 27.07M | 38.45M | 57.01M | 86.11M | 86.56M | 78.75M | 88.89M |
EBIT | 13.69M | 25.99M | 35.44M | 71.35M | 164.82M | 220.3M | 59.21M | -6.3M | 85.56M | 88.41M |
Net Interest Income | -6.44M | -6.71M | -9.29M | -10.39M | -12.54M | 4M | -10.03M | -22.57M | 4.4M | -5.55M |
Interest Income | 0 | 0 | 0 | 1.74M | 176K | 6.98M | 0 | 0 | 27.57M | 27.24M |
Interest Expense | 6.44M | 6.71M | 9.29M | 12.13M | 12.71M | 2.98M | 10.03M | 22.57M | 23.17M | 33.55M |
Other Income/Expense | -6.76M | -4.55M | -13.93M | -22.07M | -13.71M | -5.53M | 9M | 8.08M | 2.81M | -9.01M |
Pretax Income | 7.25M▲ 0% | 21.44M▲ 195.8% | 26.15M▲ 22.0% | 59.22M▲ 126.4% | 153.54M▲ 159.3% | 219.14M▲ 42.7% | 56.71M▼ 74.1% | -27.04M▼ 147.7% | 62.38M▲ 330.7% | 56.21M▲ 0% |
Pretax Margin % | 5.13% | 11.05% | 9.68% | 16.17% | 22.9% | 27.34% | 8.97% | -4.26% | 8.45% | 7.36% |
Income Tax | -21.11M | 4.82M | 4.74M | -709K | 25.25M | 33.18M | 21.11M | -1.52M | 13.49M | 4.82M |
Effective Tax Rate % | -291.18% | 22.48% | 18.13% | -1.2% | 16.45% | 15.14% | 37.23% | 5.63% | 21.62% | 8.57% |
Net Income | 28.35M▲ 0% | 16.62M▼ 41.4% | 21.41M▲ 28.8% | 59.93M▲ 179.9% | 128.29M▲ 114.1% | 185.96M▲ 45.0% | 35.6M▼ 80.9% | -25.51M▼ 171.7% | 48.89M▲ 291.6% | 51.4M▲ 0% |
Net Margin % | 20.07% | 8.56% | 7.92% | 16.36% | 19.13% | 23.2% | 5.63% | -4.02% | 6.62% | 6.73% |
Net Income Growth % | 142.73% | -41.39% | 28.85% | 179.88% | 114.08% | 44.95% | -80.86% | -171.68% | 291.64% | 323.66% |
Net Income (Continuing) | 28.35M | 16.62M | 21.41M | 59.93M | 128.29M | 185.96M | 35.6M | -25.51M | 48.89M | 51.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.72▲ 0% | 0.37▼ 48.6% | 0.44▲ 18.9% | 1.11▲ 152.3% | 2.24▲ 101.8% | 3.24▲ 44.6% | 0.63▼ 80.6% | -0.46▼ 173.0% | 0.86▲ 287.0% | 0.91▲ 0% |
EPS Growth % | 111.76% | -48.61% | 18.92% | 152.27% | 101.8% | 44.64% | -80.56% | -173.02% | 286.96% | 842.57% |
EPS (Basic) | 0.74 | 0.38 | 0.44 | 1.14 | 2.33 | 3.35 | 0.64 | -0.46 | 0.87 | - |
Diluted Shares Outstanding | 39.15M | 45.47M | 49.21M | 53.89M | 57.26M | 57.45M | 56.38M | 55.94M | 56.56M | 56.67M |
Basic Shares Outstanding | 38.23M | 43.77M | 48.34M | 52.55M | 55.02M | 55.46M | 55.72M | 55.94M | 56.23M | 56.35M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RGEN Balance Sheet
Repligen Corporation (RGEN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 242.78M | 275.74M | 641.83M | 902.38M | 931.68M | 998.12M | 1.11B | 1.07B | 1.14B | 1.16B |
Cash & Short-Term Investments | 173.76M | 193.82M | 528.39M | 717.29M | 603.81M | 623.76M | 751.32M | 757.36M | 767.63M | 784.53M |
Cash Only | 173.76M | 193.82M | 528.39M | 717.29M | 603.81M | 523.46M | 751.32M | 757.36M | 566.02M | 582.65M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 100.3M | 0 | 0 | 201.61M | 201.88M |
Accounts Receivable | 27.74M | 35.75M | 43.67M | 71.39M | 117.42M | 116.25M | 124.16M | 134.12M | 158.59M | 151.55M |
Days Sales Outstanding | 71.68 | 67.26 | 58.98 | 71.14 | 63.92 | 52.94 | 71.67 | 77.16 | 78.41 | 73.64 |
Inventory | 39M | 42.26M | 54.83M | 95.03M | 184.49M | 238.28M | 202.32M | 142.96M | 170.46M | 179.26M |
Days Inventory Outstanding | 212.33 | 179.47 | 151.6 | 201.76 | 241.12 | 251.49 | 208.65 | 145.03 | 159.27 | 213.97 |
Other Current Assets | 1.38M | 2.43M | 12.13M | 14.09M | 19.27M | 17.41M | 19.92M | 20.6M | 27.14M | 46.02M |
Total Non-Current Assets | 500.74M | 498.88M | 758.28M | 1B | 1.43B | 1.53B | 1.72B | 1.76B | 1.81B | 1.77B |
Property, Plant & Equipment | 22.42M | 32.18M | 74.16M | 92.05M | 226.52M | 315.7M | 322.95M | 333.12M | 306.15M | 287.11M |
Fixed Asset Turnover | 6.30x | 6.03x | 3.64x | 3.98x | 2.96x | 2.54x | 1.96x | 1.90x | 2.41x | 2.49x |
Goodwill | 327.33M | 326.74M | 468.41M | 618.3M | 860.36M | 855.51M | 987.12M | 1.03B | 1.11B | 1.11B |
Intangible Assets | 144.75M | 135.44M | 212.55M | 287.1M | 337.27M | 360.62M | 406.96M | 397.9M | 386.15M | 368.19M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.99M |
Other Non-Current Assets | 6.23M | 174K | 238K | 573K | 615K | 815K | 1.28M | 868K | 4.91M | 3.89M |
Total Assets | 120.41M▲ 0% | 139.45M▲ 15.8% | 1.4B▲ 904.0% | 1.9B▲ 35.9% | 2.36B▲ 23.9% | 2.53B▲ 7.3% | 2.83B▲ 11.8% | 2.83B▼ 0.1% | 2.95B▲ 4.2% | 2.93B▲ 0% |
Asset Turnover | 1.17x | 1.39x | 0.19x | 0.19x | 0.28x | 0.32x | 0.22x | 0.22x | 0.25x | 0.26x |
Asset Growth % | -58.32% | 15.81% | 904.03% | 35.91% | 23.94% | 7.35% | 11.83% | -0.05% | 4.24% | 11.67% |
Total Current Liabilities | 25.21M | 129.84M | 48.31M | 318.96M | 375.26M | 404.2M | 164.94M | 126.79M | 135.83M | 126.21M |
Accounts Payable | 7.28M | 10.49M | 11.43M | 16.88M | 36.2M | 27.55M | 19.56M | 32.13M | 30.01M | 34.66M |
Days Payables Outstanding | 39.64 | 44.54 | 31.59 | 35.84 | 47.31 | 29.08 | 20.18 | 32.6 | 28.04 | 38.47 |
Short-Term Debt | 0 | 103.49M | 0 | 243.74M | 255.26M | 284.62M | 69.45M | 0 | 21.56M | 21.07M |
Deferred Revenue (Current) | 960K | 1.29M | 5M | 15.32M | 14.68M | 19.28M | 17.07M | 13.24M | 14.61M | 69.4M |
Other Current Liabilities | 9.56M | 9.95M | 19.85M | 20.29M | 42.15M | 47.47M | 29.64M | 49.29M | 25.91M | 25M |
Current Ratio | 9.63x | 2.12x | 13.28x | 2.83x | 2.48x | 2.47x | 6.74x | 8.41x | 8.37x | 9.20x |
Quick Ratio | 8.08x | 1.80x | 12.15x | 2.53x | 1.99x | 1.88x | 5.51x | 7.28x | 7.12x | 7.78x |
Cash Conversion Cycle | 244.37 | 202.18 | 178.99 | 237.07 | 257.72 | 275.34 | 260.14 | 189.59 | 209.64 | 249.14 |
Total Non-Current Liabilities | 126.76M | 29.21M | 292.03M | 54.78M | 233.03M | 216.7M | 701.4M | 730.16M | 707.74M | 699.1M |
Long-Term Debt | 99.25M | 0 | 232.77M | 0 | 0 | 0 | 510.14M | 525.57M | 542.21M | 546.59M |
Capital Lease Obligations | 0 | 0 | 27M | 26.43M | 102.49M | 131.39M | 126.58M | 145.58M | 126.18M | 514.06M |
Deferred Tax Liabilities | 25.17M | 25.09M | 29.94M | 27.03M | 33.48M | 23M | 39.32M | 22.77M | 22.5M | 80.97M |
Other Non-Current Liabilities | 2.34M | 4.13M | 2.33M | 1.32M | 97.05M | 62.31M | 25.35M | 36.24M | 15.32M | 17.53M |
Total Liabilities | 151.97M | 159.05M | 340.35M | 373.74M | 608.29M | 620.9M | 866.34M | 856.95M | 843.57M | 825.31M |
Total Debt | 99.25M | 103.49M | 263.32M | 275.42M | 366.05M | 422.96M | 711.8M | 686.25M | 689.95M | 687.62M |
Net Debt | -74.51M | -90.33M | -265.07M | -441.88M | -237.76M | -100.5M | -39.52M | -71.11M | 123.93M | 104.97M |
Debt / Equity | 0.17x | 0.17x | 0.25x | 0.18x | 0.21x | 0.22x | 0.36x | 0.35x | 0.33x | 0.33x |
Debt / EBITDA | 4.06x | 2.48x | 4.32x | 2.54x | 1.78x | 1.50x | 5.32x | 13.34x | 4.99x | 4.42x |
Net Debt / EBITDA | -3.05x | -2.16x | -4.35x | -4.08x | -1.16x | -0.36x | -0.30x | -1.38x | 0.90x | 0.68x |
Interest Coverage | 2.13x | 3.87x | 3.81x | 5.88x | 12.96x | 74.00x | 5.91x | -0.28x | 3.69x | 2.64x |
Total Equity | 591.55M▲ 0% | 615.57M▲ 4.1% | 1.06B▲ 72.2% | 1.53B▲ 44.3% | 1.75B▲ 14.4% | 1.91B▲ 9.2% | 1.96B▲ 2.8% | 1.97B▲ 0.4% | 2.11B▲ 6.8% | 2.11B▲ 0% |
Equity Growth % | 250.52% | 4.06% | 72.16% | 44.29% | 14.45% | 9.18% | 2.83% | 0.4% | 6.76% | 19.89% |
Book Value per Share | 15.11 | 13.54 | 21.54 | 28.37 | 30.56 | 33.26 | 34.85 | 35.27 | 37.24 | 37.16 |
Total Shareholders' Equity | 591.55M | 615.57M | 1.06B | 1.53B | 1.75B | 1.91B | 1.96B | 1.97B | 2.11B | 2.11B |
Common Stock | 436K | 439K | 521K | 548K | 553K | 556K | 558K | 561K | 563K | 564K |
Retained Earnings | -31.51M | -15.57M | 5.84M | 65.77M | 194.06M | 397.27M | 432.87M | 407.35M | 456.25M | 464.58M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -6.36M | -11.89M | -15.03M | 2.08M | -16.89M | -34.39M | -37.81M | -52.53M | -2.53M | -14.31M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RGEN Cash Flow Statement
Repligen Corporation (RGEN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 17.45M | 32.77M | 67.22M | 62.63M | 119.02M | 172.08M | 113.92M | 175.39M | 117.42M | 130.71M |
Operating CF Margin % | 12.36% | 16.89% | 24.87% | 17.1% | 17.75% | 21.47% | 18.01% | 27.65% | 15.9% | - |
Operating CF Growth % | 132.03% | 87.78% | 105.11% | -6.83% | 90.05% | 44.59% | -33.8% | 53.97% | -33.06% | 19.52% |
Net Income | 28.35M | 16.62M | 21.41M | 59.93M | 128.29M | 185.96M | 41.58M | -25.51M | 48.89M | 51.4M |
Depreciation & Amortization | 10.51M | 15.78M | 20.87M | 27.07M | 38.45M | 57.01M | 68.08M | 86.56M | 96.96M | 83.67M |
Stock-Based Compensation | 6.75M | 10.19M | 12.85M | 17.01M | 27.5M | 27.32M | 25.57M | 48.07M | 32.6M | 16.36M |
Deferred Taxes | -24.68M | 71K | -624K | -3.99M | 6.52M | -1.35M | 2.32M | 0 | 0 | -2.17M |
Other Non-Cash Items | 4.04M | 4.25M | 15.33M | 11.97M | 20.39M | -27.01M | -15M | 5.36M | -10.16M | 36.17M |
Working Capital Changes | -7.52M | -14.13M | -2.62M | -49.35M | -102.13M | -69.84M | -8.64M | 60.92M | -50.88M | -46.39M |
Change in Receivables | -6.89M | -6.1M | -5.68M | -20.89M | -46.52M | -3.6M | -3.31M | -14.03M | -17.16M | -4.06M |
Change in Inventory | 605K | -4.04M | -10.8M | -29.99M | -89.78M | -57.2M | 40.97M | 56.9M | -14.95M | -23.19M |
Change in Payables | 807K | 2.27M | 662K | 2.46M | 19.52M | -8.2M | -9.8M | 12.9M | -4.15M | 8.46M |
Cash from Investing | -98.25M | -14.04M | -205.31M | -201.38M | -221.17M | -233.24M | -123.28M | -86.38M | -298.47M | -228.35M |
Capital Expenditures | -5.45M | -14.04M | -18.5M | -22.45M | -71.28M | -84.83M | -36.22M | -25.68M | -23.52M | -25.35M |
CapEx % of Revenue | 3.86% | 7.23% | 6.85% | 6.13% | 10.63% | 10.58% | 5.73% | 4.05% | 3.19% | 3.32% |
Acquisitions | -112.8M | 0 | -182.15M | -175.04M | -149.89M | 0 | -186.64M | -54.77M | -70.33M | -608K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 450K | -3.4M | -4.65M | -3.89M | 0 | -48.4M | -2.73M | -5.94M | -4.37M | -3.51M |
Cash from Financing | 129.94M | 3.41M | 484.87M | 305.92M | 961K | -13.34M | 248.96M | -82.9M | -15.21M | -15.72M |
Debt Issued (Net) | 0 | -11K | 163.48M | 0 | -21K | 0 | 290.09M | -69.94M | 0 | 0 |
Equity Issued (Net) | 129.31M | 0 | 320.71M | 297.77M | 3.88M | 0 | -14.39M | 4.29M | 0 | -28.8M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -14.39M | 0 | 0 | -14.34M |
Other Financing | 636K | 3.42M | 677K | 8.14M | -2.9M | -13.34M | -26.75M | -17.26M | -15.21M | 13.08M |
Net Change in Cash | 51.53M▲ 0% | 20.06M▼ 61.1% | 343.58M▲ 1612.5% | 179.88M▼ 47.6% | -113.48M▼ 163.1% | -80.36M▲ 29.2% | 227.87M▲ 383.6% | 6.03M▼ 97.4% | -191.33M▼ 3272.0% | -114.58M▲ 0% |
Free Cash Flow | 12M▲ 0% | 18.73M▲ 56.1% | 44.06M▲ 135.2% | 36.28M▼ 17.7% | 47.74M▲ 31.6% | 38.74M▼ 18.9% | 74.93M▲ 93.4% | 142.49M▲ 90.2% | 93.9M▼ 34.1% | 104.35M▲ 0% |
FCF Margin % | 8.49% | 9.65% | 16.3% | 9.91% | 7.12% | 4.83% | 11.85% | 22.46% | 12.72% | 13.67% |
FCF Growth % | 275.38% | 56.15% | 135.21% | -17.66% | 31.58% | -18.86% | 93.43% | 90.16% | -34.1% | -12.85% |
FCF per Share | 0.31 | 0.41 | 0.90 | 0.67 | 0.83 | 0.67 | 1.33 | 2.55 | 1.66 | 1.84 |
FCF Conversion (FCF/Net Income) | 0.62x | 1.97x | 3.14x | 1.05x | 0.93x | 0.93x | 3.20x | -6.87x | 2.40x | 2.03x |
Interest Paid | 2.44M | 2.44M | 1.48M | 1.07M | 0 | 1.03M | 988K | 6.07M | 0 | 0 |
Taxes Paid | 4.02M | 4.05M | 6.5M | 10.28M | 0 | 34.37M | 26.96M | 19.3M | 0 | 0 |
RGEN Key Ratios
Repligen Corporation (RGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.46% | 2.75% | 2.56% | 4.63% | 7.82% | 10.16% | 1.84% | -1.3% | 2.4% | 2.46% |
Return on Invested Capital (ROIC) | 3.29% | 3.74% | 4.56% | 6.48% | 9.65% | 10.14% | 1.92% | -1.38% | 2.16% | 2.35% |
Gross Margin | 52.53% | 55.7% | 51.15% | 53.06% | 58.35% | 56.85% | 44.03% | 43.29% | 47.09% | 51.53% |
Net Margin | 20.07% | 8.56% | 7.92% | 16.36% | 19.13% | 23.2% | 5.63% | -4.02% | 6.62% | 6.73% |
Debt / Equity | 0.17x | 0.17x | 0.25x | 0.18x | 0.21x | 0.22x | 0.36x | 0.35x | 0.33x | 0.33x |
Interest Coverage | 2.13x | 3.87x | 3.81x | 5.88x | 12.96x | 74.00x | 5.91x | -0.28x | 3.69x | 2.64x |
FCF Conversion | 0.62x | 1.97x | 3.14x | 1.05x | 0.93x | 0.93x | 3.20x | -6.87x | 2.40x | 2.03x |
Revenue Growth | 35.1% | 37.38% | 39.28% | 35.53% | 83.08% | 19.54% | -21.11% | 0.33% | 16.36% | 17.36% |
Related:RGEN Dividend History·RGEN Revenue History·RGEN Price History·RGEN P/E History·RGEN Financial Ratios·RGEN Institutional Holders
RGEN SEC Filings & Documents
Repligen Corporation (RGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)
RGEN Frequently Asked Questions
Repligen Corporation (RGEN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Repligen Corporation (RGEN) reported $763.3M in revenue for fiscal year 2025. This represents a 6903% increase from $10.9M in 1996.
Repligen Corporation (RGEN) grew revenue by 16.4% over the past year. This is strong growth.
Yes, Repligen Corporation (RGEN) is profitable, generating $51.4M in net income for fiscal year 2025 (6.6% net margin).
Dividend & Returns
Repligen Corporation (RGEN) has a return on equity (ROE) of 2.4%. This is below average, suggesting room for improvement.
Repligen Corporation (RGEN) generated $104.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.